New York, New York--(Newsfile Corp. - March 26, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the ordinary shares of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive.Should You Join The uniQure Class Action Lawsuit:Do you, or did you, own shares of uniQure N.V. (QURE)?Did you purchase your shares between September 24, 202 ...

New York, New York--(Newsfile Corp. - March 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V. Investor Summary Who: uniQure N.V. (NASDAQ: QURE)What: Securities fraud class action lawsuit filedClass Period: September 24, 2025, and October 31, 2025Deadline to Seek Lead Plaintiff Status: April 13, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s Huntington’s disease gene therapy drug.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.c ...

uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed; April 13, 2026, Lead Plaintiff Deadline Accessibility StatementSkip Navigation Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V. Investor Summary RADNOR, Pa., March 24, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLPinforms investors that the firm has filed a securities fraud class action lawsuitagainst uniQure N.V. (NASDAQ: QURE) (uniQure) on behalf of investors who purchased or a ...

The recent reports follow the filing of a securities class action suit. The FDA Clash: "A Distorted or Manipulated Comparison" On March 5 and 6, 2026, media outlets including The Wall Street Journal, CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure. The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the mind of FDA" instead of running a ...

Shareholders who purchased shares of QURE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. QURE Shareholder Alert: uniQure N.V. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm Accessibility StatementSkip Navigation NEW YORK, March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (N ...

Philadelphia, Pennsylvania--(Newsfile Corp. - March 24, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) ("uniQure" or the "Company") on behalf of investors who purchased or otherwise acquired uniQure securities during the period from September 24, 2025 through October 31, 2025 (the "Class Period"). Investor Deadline: Investors who purchased uniQure securities during the Class Period may, no later than April 13 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the April 13, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought uniQure shares during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 13, 2026, to serve as lead plaintiff [2] - The lawsuit claims that uniQure misrepresented and/or failed to disclose critical information regarding its Pivotal Study and the likelihood of delays in its Biologics License Application (BLA) timeline [4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [3] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3]

Core Viewpoint - Hagens Berman is conducting an investigation into uniQure N.V. following significant criticisms from the FDA regarding the company's gene therapy candidate AMT-130, which has been labeled a "failed therapy" and accused of using distorted data in clinical comparisons [1][2]. Group 1: FDA Allegations - An FDA official criticized uniQure for allegedly performing a "distorted or manipulated comparison" in its clinical studies instead of adhering to proper protocols [2]. - The FDA has not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, indicating a lack of regulatory consensus on the therapy's evaluation [5]. Group 2: Class Action Lawsuit Details - The securities class action lawsuit, Scocco v. uniQure N.V., alleges that uniQure misrepresented its interactions with the FDA and failed to disclose critical information regarding its clinical study design [3][4]. - Specific allegations include mischaracterization of sham surgeries, denial of prior agreements with the FDA, and misleading statements about the eligibility of AMT-130 for streamlined pathways [4][5]. Group 3: Impact on Investors - The stock price of uniQure fell by 49% following the revelation of the lack of FDA agreement on the Biologics License Application (BLA) timeline, which was previously presented as clear [5]. - Investors who purchased shares during the class period (September 24, 2025 – October 31, 2025) are reminded of the April 13, 2026, deadline to apply as Lead Plaintiff in the ongoing lawsuit [6].

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for misleading investors regarding its gene therapy drug AMT-130 during the specified Class Period [2][4][5]. Group 1: Lawsuit Details - The lawsuit was filed by Kessler Topaz Meltzer & Check, LLP on behalf of investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025 [2][7]. - The deadline for investors to seek lead plaintiff status is April 13, 2026 [3][9]. - The case is titled Scocco v. uniQure N.V., et al., and is being heard in the United States District Court for the Southern District of New York [2]. Group 2: Allegations Against uniQure - The complaint alleges that uniQure made materially false and misleading statements regarding its Phase I/II clinical trials and the timeline for its Biologics License Application (BLA) submission to the FDA [4][5]. - Specific allegations include that the design of the Pivotal Study was not fully approved by the FDA and that uniQure downplayed the likelihood of needing to delay its BLA timeline due to additional studies [5][6]. - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from the Phase I/II studies would be adequate for BLA submission, leading to a significant drop in share price [6][8]. Group 3: Impact on Share Price - Following the disclosure on November 3, 2025, uniQure's share price fell by $33.40, or over 49%, from $67.69 to $34.29 per share [8].